PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

Gene genies: Oxford Biomedica and Homology Medicines create AAV business

Leading gene and cell therapy group, Oxford Biomedica, and Homology Medicines, have announced that the companies will establish a high-performing Adeno-Associated Virus (AAV) Manufacturing and Innovation Business in the US.

Oxford Biomedica aims to establish a presence across the pond and will offer pharmaceutical and biotechnology manufacturing expertise in AAV and lentiviral-based gene therapies. In addition, the deal will provide access to Homology’s proven end-to-end manufacturing toolbox.

Under the terms of the agreement, Oxford Bionmedica will pay Homology $130m upfront and invest $50m to fund Oxford Biomedica Solutions, in return for an 80% ownership stake, while Homology will also own 20% of the new company. The transaction is expected to close in the first quarter of 2022, depending on the satisfaction of certain closing conditions.

Dr Roch Doliveux, Chair and interim CEO of Oxford Biomedica, commented on the development: “Accessing Homology Medicines’ unique AAV capabilities is a major advancement in Oxford Biomedica’s goal to become an innovative global viral vector leader that provides solutions to Cell and Gene Therapy (C>) Biotech and Biopharma companies for their process development and manufacturing needs across key viral vectors.

He added: “Process Development/CMC being one of the most important critical success factors to ensure efficacy, safety and affordability of C>, Oxford Biomedica is in a strong position to enable our customers to bring their new medicines to many more patients and change their lives.

“We look forward to working with Homology’s impressive team and uniquely robust processes to achieve world-leadership as a provider of AAV solutions in addition to enhancing our leadership in lentiviral vectors. Having a US base brings us closer to customers, talent, innovation in academia and pools of capital all of which will allow growth and building a market leadership position.”

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026